Jim Miller
Jim Miller is a member of PharmTech's editorial advisory board (EAB) and is a contributing editor to the magazine.
Jim Miller
President, PharmSource Information Services,
Bio/Pharmaceutical Outsourcing Report
PharmTech Contributing editor, Outsourcing Outlook
Jim Miller is the founder and president of PharmSource. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the pharmaceutical industry’s principal source of market intelligence on the business of contract research, development and manufacturing of bio/pharmaceuticals. PharmSource’s subscription databases, reports and consulting services are used by major pharmaceutical companies, contract manufacturers and contract research organizations to understand key market trends, identify new business opportunities and establish effective business and sourcing strategies. Jim writes regular columns on outsourcing for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm magazines.
Jim’s other career highlights include a stint as president and chief operating officer of St. Anthony Publishing, a pioneering provider of value-added information services to hospitals and physician practices. He was a consultant in corporate strategy with the Boston Consulting Group, a project economist for the World Bank, and a Peace Corps volunteer in Botswana. He holds an MBA degree from the Stanford University Graduate School of Business.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes
May 9th 2025A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.
